These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 9096441)

  • 1. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
    Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
    Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
    Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
    Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.
    Chen CL; Chen NC; Hsu CY; Chou KJ; Lee PT; Fang HC; Renn JH
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2426-32. PubMed ID: 24670088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
    Fukagawa M; Kitaoka M; Yi H; Fukuda N; Matsumoto T; Ogata E; Kurokawa K
    Nephron; 1994; 68(2):221-8. PubMed ID: 7830860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
    Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
    Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
    Malberti F; Surian M; Cosci P
    Nephrol Dial Transplant; 1992; 7(8):822-8. PubMed ID: 1325615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol.
    Sprague SM; Moe SM
    Am J Kidney Dis; 1992 Jun; 19(6):532-9. PubMed ID: 1595701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
    Torun D; Yildiz I; Micozkadioglu H; Nursal GN; Yigit F; Ozelsancak R
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):15-22. PubMed ID: 26787561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy.
    Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N
    Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.